Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gubra A/S (GUBRA.CO)
Horsholm, DK
Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.18% | +3.59% | +12.60% | -8.59% | -27.33% | -33.07% | -9.47% | +262.88% | +224.91% | +224.91% | +224.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+892.3% ★ Q4'25: +40.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+4,684.8% ★ Q4'25: -173.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+66.2% Q4'25: -418.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+84.2% ★ Q4'25: -49.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+672.0% ★ Q4'25: -110.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q4'25: +0.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.09× ★ Q4'25: -0.72× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
205.01M
est: 257.00M (-20.2%)
|
265.74M
est: 256.43M (+3.6%)
|
2.64B
est: 2.63B (+0.1%)
|
537.62M
264.16M – 811.08M
-79.6% YoY
|
632.11M
285.79M – 978.43M
+17.6% YoY
|
1.03B
483.39M – 1.58B
+63.3% YoY
|
814.68M
381.44M – 1.25B
-21.1% YoY
|
1.53B
714.51M – 2.34B
+87.3% YoY
|
| EBITDA |
-28.06M
est: 17.55M (-259.9%)
|
-20.06M
est: 54.60M (-136.7%)
|
2.23B
est: 560.87M (+298.3%)
|
114.46M
56.24M – 172.68M
-79.6% YoY
|
134.58M
60.85M – 208.31M
+17.6% YoY
|
219.81M
102.92M – 336.70M
+63.3% YoY
|
173.45M
81.21M – 265.69M
-21.1% YoY
|
324.91M
152.12M – 497.69M
+87.3% YoY
|
| EBIT |
-38.01M
est: 8.02M (-573.8%)
|
-35.82M
est: 46.68M (-176.7%)
|
2.22B
est: 479.53M (+363.0%)
|
97.86M
48.09M – 147.64M
-79.6% YoY
|
115.07M
52.02M – 178.11M
+17.6% YoY
|
187.94M
87.99M – 287.88M
+63.3% YoY
|
148.30M
69.43M – 227.16M
-21.1% YoY
|
277.79M
130.06M – 425.52M
+87.3% YoY
|
| Net Income |
-44.52M
est: -32.37M (-37.6%)
|
-36.50M
est: -25.31M (-44.2%)
|
1.69B
est: 1.69B (+0.0%)
|
-72.28M
-92.99M – -16.97M
-104.3% YoY
|
-37.53M
-63.48M – -11.58M
+48.1% YoY
|
450.87M
246.04M – 655.71M
+1,301.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
66.50M
est: 71.67M (-7.2%)
|
101.52M
est: 61.75M (+64.4%)
|
97.09M
est: 634.36M (-84.7%)
|
129.46M
63.61M – 195.31M
-79.6% YoY
|
152.22M
68.82M – 235.61M
+17.6% YoY
|
248.61M
116.40M – 380.82M
+63.3% YoY
|
196.18M
91.85M – 300.51M
-21.1% YoY
|
367.48M
172.06M – 562.90M
+87.3% YoY
|
| EPS |
-2.93
est: -1.99 (-47.6%)
|
-2.24
est: -1.54 (-45.7%)
|
103.83
est: 111.81 (-7.1%)
|
-3.34
-5.65 – -1.03
-103.0% YoY
|
-2.28
-3.86 – -0.70
+31.7% YoY
|
27.39
14.95 – 39.83
+1,301.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Roundhill Investments - GLP-1 & Weight Loss ETF OZEM | 2.03% | 1.29M | 0.59% |
| 2 | Tema Cardiovascular and Metabolic ETF HRTS | 0.44% | 240.5K | 0.99% |
| 3 | iShares MSCI Denmark ETF EDEN | 0.32% | 656.2K | 0.53% |
| 4 | iShares International Small-Cap Equity Factor ETF ISCF | 0.13% | 830.7K | 0.24% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.05% | 181.4K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.05% | 181.4K | 0.23% |
| 7 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.04% | 453.7K | 0.40% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.02% | 38.9K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.02% | 734.2K | 0.30% |
| 10 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 150.1K | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Markus Rohrwild | Chief Executive Officer | 3M | male |
| Kristian Borbos | Chief Financial Officer | 2M | male |
| Niels Vrang | Co-Founder & Director | 334.0K | — |
| Jacob Jelsing | Co-Founder & Director | 334.0K | male |
| Thomas Langenickel | Chief Medical and Development Officer | — | — |
| Emma Jappe Lange | Investor Relations & Strategy Lead | — | — |
| Trine Nygaard Hamann | Head of Gubra CRO | — | female |
| Grigo Gaurav | Chief Technology Officer | — | male |
| Line Holten Reimer | Chief Investment Officer | — | female |
| Louise Schjellerup Dalboge | Chief Science Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GUBRA.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
